M a t i T h e r a p e u t i c s I n c .

1

bbutchofsky@matitherapeutics.com cmuller@matitherapeutics.com

Designed and tested over 70 different iterations including “arrow” and “L”

shapes among others

Barrel L Design Arrowhead L Design

Straight L Design

Arrow Design

Retention rate of initial L-PPDS GLAU12 = 96% GLAU13 = 92%

High Retention rate continues on repeat insertion of L-PPDS 2nd cycle (8 weeks) = 97%

Solid drug-eluting core placed into our silicon punctal plug

Drug core wrapped in a non-permeable membrane and sealed with medical adhesive

Provides for one-directional drug release – directly into the tear film

X

X

X

Glaucoma Allergy Anti-Inflammatory Dry Eye

Prostglandins Mast Cell Stabilizers Steroids Soft Steroids

Beta-Blockers Antihistamines NSAIDs NSAIDs

Alpha Agonists OTC Demulcents

NCEs (ROK?) NCEs

Glaucoma Allergy Anti-Inflammatory Dry Eye

Prostglandins(Latanoprost, Brimatoprost, Travoprost)

Mast Cell Stabilizers Steroids Soft Steroids

Beta-Blockers Antihistamines NSAIDs(Nepafenac, Bromfenac)

NSAIDs

Alpha Agonists Olopatadine OTC Demulcents

NCEs (ROK?) NCEs

Mati now has 5 fully formulated ophthalmic agents including PGs, NSAIDs, and Mast Cell Stabilizers/Antihistamines.

-6.09

-5.35 -5.44-5.07

-5.56

-4.88-5.3

-5.06

-7

-6

-5

-4

-3

-2

-1

0

WK 1 WK 2 WK 3 WK 4 WK 6 WK 8 WK 10 WK 12

95% CI*Wk 4: (-6.11, -4.04), Wk 8: (-5.77, -3.99), Wk12:(-6.20, -3.93)

Ch

ang

e in

IOP

(mm

Hg

)

*95% CI excludes 0, indicating a p-value of <.05All IOP included, regardless of plug loss/removal

Adverse Event Percentage

Lacrimation (tearing) 13.1%

Eye Pruritis (itching) 10.7%

Conjunctival Hyperemia (redness) 7.6%

Punctate Keratitis (form of cornea inflammation) 6.7%

Eyelid Erythema (redness) 1.7%

Photophobia (light sensitivity) 0.5%

All Studies at 95µg Plug Concentration or Less, N=421

Serious AEs

Serious Adverse Event Occurrence

Skin Erosion 1 patient

Systemic 2 patients

0

2

4

6

8

10

12

14

0 5 10 15 20 25 30

Dru

g E

luti

on

Ra

te u

g/d

ay

Time (days)

L-PPDS

50% T-PPDS

30% T-PPDS

Beta-Blocker

Travoprost

0.00

2.00

4.00

6.00

8.00

10.00

12.00

14.00

16.00

18.00

20.00

0 5 10 15 20 25 30

Elu

tio

n r

ate

(m

icro

g/d

ay

)

Time (Days)

• Target elution : 3 μg/day for two weeks

Target μgFor desired efficacy

Initial burst is tunable to extend duration of action or power of

initial dose

IP portfolio consists of 62 issued patents and approximately 106 pending applications, comprising 15 patent families:

▪ Drug Core Design and Formulation▪ Lacrimal Implants▪ Manufacturing▪ Tools▪ Method of Use

Patent protection currently extends from approximately 2027-2034

Formulation Preclinical Phase I Phase II Phase III

Evolute® GlaucomaLatanoprost

Evolute® GlaucomaTravoprost

Evolute® Allergy(Olopatadine)

Evolute® Anti-Inflammatory(NSAID and/or steroid)

Multiple product opportunities for development from this platform• Allergy, Inflammation (NSAIDs & Steroids), Glaucoma (PGs, BetaBlockers, CAIs, Alpha 2s), Dry Eye

Wide Range of Compounds that can be Formulated Flexible Drug Delivery Profile Non-Invasive Approach Provides Relatively Steady Elution – Unlike Eye Drops Mati Plug is Comfortable and has Excellent Retention Preservative Free “Passive” System for Patients → Physician Controls Compliance

Reimbursement Paradigm Shift for General Ophthalmologists, Glaucoma Specialists, and Optometry

Strong IP Protection Reasonable COGS Projections